As there is an increasing number of cancer treatments in which IFNα is at play (see e.g. Sistigu et al., 2014 for example), TGFβ-dependent inhibition of IFNβ/α signaling is likely to be involved in numerous treatment-resistance phenomena. This evidence concerns the gene TGFB1 and cancer.